10178- ACT-11 A PHASE 1 STUDY OF LOMUSTINE MONOTHERAPY AND COMBINATION THERAPY WITH PROCARBAZINE, LOMUSTINE, AND VINCRISTINE IN JAPANESE PATIENTS WITH GLIOMA (LOMG)
Yoshiki Arakawa, Yasuhide Makino, Etsuko Yamamoto, Yasuhide Takeuchi, Shigeki Takada, Noritaka Sano, Masahiro Tanji, Yohei Mineharu, Atsushi Yonezawa · 2024
Read 10178- ACT-11 A PHASE 1 STUDY OF LOMUSTINE MONOTHERAPY AND COMBINATION THERAPY WITH PROCARBAZINE, LOMUSTINE, AND VINCRISTINE IN JAPANESE PATIENTS WITH GLIOMA (LOMG) by Yoshiki Arakawa, Yasuhide Makino, Etsuko Yamamoto, Yasuhide Takeuchi, Shigeki Takada, Noritaka Sano, Masahiro Tanji, Yohei Mineharu, Atsushi Yonezawa (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11605617.txt.
Description
Yoshiki Arakawa and co-authors describe a planned phase 1 trial in Japan for glioma, a type of brain tumor, in a report from 2024. The trial tests a drug called lomustine alone and a three-drug mix that uses it with two other drugs.
The report gives the background for the trial. The three-drug mix is standard care in many countries for some gliomas and can extend life, but lomustine is not approved in Japan. A national review in 2022 found that a trial with Japanese patients was needed first. The physician-led trial began in 2023.
Catalog record
| CREATOR | Yoshiki Arakawa, Yasuhide Makino, Etsuko Yamamoto, Yasuhide Takeuchi, Shigeki Takada, Noritaka Sano, Masahiro Tanji, Yohei Mineharu, Atsushi Yonezawa |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 2 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |